Psyence Biomedical LTD Schedule 13G passive stakes

Jeffrey David Weiner has filed a Schedule 13G, reporting beneficial ownership of 59,750 shares, representing 2.61% of Psyence Biomedical Ltd.'s common stock.

Jeffrey David Weiner has reported a beneficial ownership of 5.07% of PSYENCE BIOMEDICAL LTD.'s Common Shares.

Harraden Circle Investments and its affiliated entities have filed an amendment to their Schedule 13G, reporting that they no longer beneficially own more than five percent of Psyence Biomedical Ltd.'s Class A Common Stock.

Hudson Bay Capital Management LP and Sander Gerber have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Psyence Biomedical Ltd., primarily through warrants subject to a beneficial ownership blocker.

Harraden Circle Investments, LLC and its affiliated entities have filed an amended Schedule 13G, reporting a passive beneficial ownership of 5.32% of Psyence Biomedical Ltd.'s Class A Common Stock as of December 31, 2024.

Hudson Bay Capital Management LP and Sander Gerber have filed an amended Schedule 13G, revealing a combined beneficial ownership of 9.98% in Psyence Biomedical Ltd.'s common shares.

Hudson Bay Capital Management LP and Sander Gerber have disclosed a beneficial ownership of 9.98% in Psyence Biomedical Ltd., totaling 380,000 common shares.

AdvisorShares Trust has filed an amended Schedule 13G, disclosing a beneficial ownership of 0.79% of PSYENCE BIOMEDICAL LTD.'s Common Shares as of December 31, 2024.